Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
← catalyst calendarNCT07626411 · readout in 1,119 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
Phase 3
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
15,364estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-07-31 | estimated | When the study began enrolling |
| Primary completion | 2029-09-11 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-12-10 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-04 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Atrial Fibrillation (AF)
Interventions
- Drug: REGN7508 — also filed as cenvacibart
- Drug: Apixaban
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFTime to first occurrence of stroke (ischemic, hemorrhagic, or of unspecified type) or systemic embolism
measured Approximately 36 months
Time to first occurrence of International Society on Thrombosis and Haemostasis (ISTH) major bleeding or ISTH Clinically Relevant Non-Major (CRNM) bleeding
measured Approximately 36 months
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed